PRASAD SUYASH
Known title: CMO and Head of R&DCIK: 0001679129
Associated companies
Transaction History
| TSHA | ▼ Sell | Open Market | 8,956 | $34K | 7/6/2022 | View on chart |
| TSHA | ▼ Sell | Open Market | 3,905 | $14K | 7/5/2022 | View on chart |
| TSHA | ▼ Sell | Open Market | 23,923 | $84K | 7/1/2022 | View on chart |
| TSHA | ▼ Sell | Open Market | 13,892 | $52K | 6/30/2022 | View on chart |
| TSHA | ▼ Sell | Open Market | 12,324 | $47K | 6/29/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
TSHA Valuation Debate Highlights Split Views
Recent articles discuss conflicting views on Taysha Gene Therapies' valuation, with some suggesting the stock is above fair value based on book value, while others argue it may be undervalued. This debate occurs while the stock trades near its 52-week low, reflecting significant uncertainty among investors regarding the company's true worth.
TSHA Valuation Debate Highlights Split Views. Recent articles discuss conflicting views on Taysha Gene Therapies' valuation, with some suggesting the stock is above fair value based on book value, while others argue it may be undervalued. This debate occurs while the stock trades near its 52-week low, reflecting significant uncertainty among investors regarding the company's true worth.